Table 1 Baseline characteristics of all included participants
Variables | Total (n = 26,293) | Ethnic Chinese (n = 4928) | Other Asian-Americans (n = 21,365) |
|---|---|---|---|
Year of diagnosis, year, n (%) | |||
2004 | 2265 (8.61) | 426 (8.64) | 1839 (8.61) |
2005 | 2128 (8.09) | 426 (8.64) | 1702 (7.97) |
2006 | 2279 (8.67) | 469 (9.52) | 1810 (8.47) |
2007 | 2524 (9.60) | 517 (10.49) | 2007 (9.39) |
2008 | 2303 (8.76) | 477 (9.68) | 1826 (8.55) |
2009 | 2364 (8.99) | 448 (9.09) | 1916 (8.97) |
2010 | 2278 (8.66) | 430 (8.73) | 1848 (8.65) |
2011 | 2367 (9.00) | 412 (8.36) | 1955 (9.15) |
2012 | 1979 (7.53) | 374 (7.59) | 1605 (7.51) |
2013 | 1913 (7.28) | 302 (6.13) | 1611 (7.54) |
2014 | 1854 (7.05) | 307 (6.23) | 1547 (7.24) |
2015 | 2039 (7.75) | 340 (6.90) | 1699 (7.95) |
Age at diagnosis, years, n (%) | |||
< 65 | 10,484 (39.87) | 1737 (35.25) | 8747 (40.94) |
≥ 65 | 15,809 (60.13) | 3191 (64.75) | 12,618 (59.06) |
Marital status, n (%) | |||
Married | 19,750 (75.12) | 3826 (77.64) | 15,924 (74.53) |
Unmarried, single or widowed | 6543 (24.88) | 1102 (22.36) | 5441 (25.47) |
Histological types, n (%) | |||
Adenocarcinoma | 25,964 (98.75) | 4838 (98.17) | 21,126 (98.88) |
Squamous-cell carcinoma, mucinous carcinoma or sarcoma | 329 (1.25) | 90 (1.83) | 239 (1.12) |
Grade, n (%) | |||
I | 11,817 (44.94) | 2193 (44.50) | 9624 (45.05) |
II | 14,476 (55.06) | 2735 (55.50) | 11,741 (54.95) |
T Stage, n (%) | |||
T1 | 10,817 (41.14) | 2212 (44.89) | 8605 (40.28) |
T2 | 12,257 (46.62) | 2187 (44.38) | 10,070 (47.13) |
T3 | 2736 (10.41) | 449 (9.11) | 2287 (10.70) |
T4 | 483 (1.84) | 80 (1.62) | 403 (1.89) |
N Stage, n (%) | |||
N0 | 25,650 (97.55) | 4824 (97.89) | 20,826 (97.48) |
N1 | 643 (2.45) | 104 (2.11) | 539 (2.52) |
M Stage, n (%) | |||
M0 | 25,476 (96.89) | 4785 (97.10) | 20,691 (96.85) |
M1 | 817 (3.11) | 143 (2.90) | 674 (3.15) |
Radiotherapy, n (%) | |||
No | 25,313 (96.27) | 4769 (96.77) | 20,544 (96.16) |
Yes | 980 (3.73) | 159 (3.23) | 821 (3.84) |
Chemotherapy, n (%) | |||
No | 26,130 (99.38) | 4895 (99.33) | 21,235 (99.39) |
Yes | 163 (0.62) | 33 (0.67) | 130 (0.61) |
Surgery, n (%) | |||
No | 15,449 (58.76) | 3010 (61.08) | 12,439 (58.22) |
Yes | 10,844 (41.24) | 1918 (38.92) | 8926 (41.78) |
Regional nodes positive, n (%) | |||
No | 5845 (22.23) | 1011 (20.52) | 4834 (22.63) |
Yes | 20,448 (77.77) | 3917 (79.48) | 16,531 (77.37) |
Follow time (months), M (Q1, Q3) | 71 (38, 107) | 75 (42, 109) | 71 (38, 106) |
Outcomes, n (%) | |||
Survived at the end of the follow-up period | 21,636 (82.29) | 4077 (82.73) | 17,559 (82.19) |
Died of PCa | 1038 (3.95) | 171 (3.47) | 867 (4.06) |
Died of other causes | 3619 (13.76) | 680 (13.80) | 2939 (13.76) |